B+
Bull case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
GERN
GeronCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
RYTELO's Q1 2026 net product revenue of $51.8 million increased 8% from Q4 2025, and Geron reiterated $220 million-$240 million of 2026 RYTELO revenue guidance while reporting $341 million of cash, cash equivalents, restricted cash and marketable securities at quarter-end [#IR-2026-05-06]. Second-half clinical and real-world data or a credible European strategy could add value.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Analyst target count, estimate revisions, post-print market reaction and social coverage are unavailable; the peer set is loose.
Momentum
87
Value
41
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.30 · Bull $2.20 · Bear $0.70Analysis 2026-08-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $4.25
Why
Momentum87 · Δ7d -
Value41 · Δ7d -0.0
Sentiment66 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Analyst target count, estimate revisions, post-print market reaction and social coverage are unavailable; the peer set is loose.
- • European commercialization and expansion beyond the current approved setting remain execution-dependent.
- • The valuation remains dependent on continued commercial uptake, execution against guidance, and uncertain clinical expansion.
Catalyst clock
2026-08-05
Q2 2026 results and RYTELO execution checkpoint
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
66
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 87.1 / Value 41.2 / Sentiment 65.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-01. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$982.98M
Beta
0.62
Shares Out
642.47M
P/E (TTM) · Derived
-12.2
P/S (TTM)
4.59
P/FCF (TTM) · Derived
-8.92
Rev YoY
+17.2%
EPS YoY
+1.2%
Gross Margin
+96.4%
Op Margin
-18.4%
Net Debt
-$108.23M
Current Ratio
6.92
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data